Acute Coronary Syndrome Update (Recorded at Pri-Med Midwest)
The epidemiology of acute coronary syndromes has changed dramatically in the past few decades, with lower overall incidence of myocardial infarction (MI) -- particularly ST elevation MI -- and improved survival after an incident MI. The diagnosis and classification of MI is challenging, particularly in the era of sensitive troponin assays. Clinicians must be aware of the frequent occurrence and causes of troponin elevations from conditions other than MI. Following diagnosis, risk stratification for patients with non-ST elevation ACS is critical to making prudent decisions and selecting among the multitude of different options for invasive and medical therapies. When considering potent antiplatelet and antithrombotic therapies, it is of paramount importance to also consider bleeding risk. Primary care clinicians play a critical role in determining the optimal duration of dual antiplatelet therapy, ensuring appropriate use and adherence to evidence-based medical therapies, and addressing lifestyle factors that can help prevent or modify the course after an ACS event.
pmiCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
pmiCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following financial relationships have been disclosed by faculty.
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.